CSE:AGN - Post Discussion
Post by
StockHawk1 on Jan 17, 2023 3:11pm
AGN begins Phase 1 DMT-stroke study
Algernon Pharmaceuticals (AGN.c AGNPF) has dosed the first subject in its Phase 1 clinical study of DMT for the treatment of stroke.
In this phase of the study, AGN is dosing healthy patients with DMT to identify a safe and tolerable non-psychedelic dose.
If successful the next phase of the study will focus on the rehabilitation of acute stroke patients.
https://ca.finance.yahoo.com/news/algernon-neuroscience-doses-first-subject-120000080.html
Be the first to comment on this post